GlassScriptPhysician profile
Biren R Patel
NPI 1376579185
$3,301.85
in general payments reported to CMS, 2019-2025
28 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $356 · 2021: $545 · 2022: $258 · 2023: $248 · 2024: $229 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $602.69 | 2019-2024 | Farxiga |
| Astellas Pharma US INC | $473.60 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $464.21 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $246.00 | 2019-2024 | Capvaxive |
| Abbvie INC. | $169.93 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $150.74 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $150.11 | 2019-2020 | |
| Medtronic, INC. | $134.20 | 2022 | |
| Baxter Healthcare | $124.88 | 2021 | |
| Esperion Therapeutics, INC. | $124.48 | 2021 | |
| Amag Pharmaceuticals, INC. | $115.44 | 2019 | |
| Therapeuticsmd, INC. | $110.42 | 2019 | |
| Pfizer INC. | $57.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.37 | 2019-2020 | |
| Cordis US Corp. | $45.76 | 2025 | Mynx Control |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $40.75 | 2020 | |
| Exact Sciences Corporation | $35.38 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $27.53 | 2019 | |
| Mallinckrodt Enterprises LLC | $26.68 | 2019 | |
| Amarin Pharma, INC. | $22.04 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.39 | 2024 | |
| Lundbeck LLC | $18.37 | 2024 | Rexulti |
| Ucb, INC. | $18.19 | 2020 | |
| Kyowa Kirin, INC. | $16.44 | 2019 | |
| Medtronic USA, INC. | $14.57 | 2019 | |
| Novo Nordisk INC | $13.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.79 | 2019 | |
| Sanofi Pasteur INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biren Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.